Skip to content

Cytokine Removal by CRRT in Pediatric Sepsis

Cytokine Removal by CRRT in Pediatric Sepsis: A Comparison of Convection Versus Diffusion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00537693
Enrollment
40
Registered
2007-10-01
Start date
2007-09-30
Completion date
2010-05-31
Last updated
2010-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Continuous Renal Replacement Therapy (CRRT), Sepsis, Convection, Diffusion

Brief summary

This pilot study will compare the effect of diffusive versus convective Continuous Renal Replacement Therapy (CRRT) in children with sepsis who require CRRT. The hypothesis for the study is that convective forms of CRRT provide enhanced clearance of cytokines and improved clinical responses as compared to a diffusive CRRT modality.

Detailed description

The purpose of this study is to test the hypothesis that convective forms of Continuous Renal Replacement Therapy (CRRT) provides enhanced clearance of cytokines compared to a diffusive CRRT modality. Also, we plan to test the hypothesis that patients who receive convective CRRT modalities demonstrate improved clinical responses to patients who receive a diffusive CRRT modality.

Interventions

PROCEDUREContinuous Renal Replacement Therapy

Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.

Sponsors

Dialysis Solutions Inc.
CollaboratorINDUSTRY
Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Patients with documented sepsis or suspected SIRS * Patients initiating CRRT * Age 1 to 21 years

Exclusion criteria

* Patients on ECMO * Patients receiving concomitant plasma exchange * Cardiopulmonary bypass procedure within 96 hours of CRRT * Patients with new onset acute leukemia * Patients with active autoimmune disease * Ungrafted stem cell transplant recipients

Design outcomes

Primary

MeasureTime frame
A 25% additional decrease in IL-6 concentration changeThe First 24 hours of CRRT

Secondary

MeasureTime frame
Other cytokine removal ratesFirst 24 hours of CRRT
Cytokine absorption on the CRRT membraneFirst 24 hours of CRRT
Hemodynamic parametersFirst 24 hours of CRRT
Changes in serum cytokine concentrations and clearanceAfter crossover, from 24-48 hours
Changes in serum cytokine concentrationsFrom beginning to end of the study, independent of modality

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026